MicroRNA biomarkers for predicting treatment response and resistance to bevacizumab in cancer

Zahra Monzavi Chaleshtori; Sanaz Darash; Sarvenaz Parsa; Elahe Orak Sarkani; Motahareh Taghizadeh; Omid Vakili

doi:10.1016/j.cca.2025.120472

journal article Sep 01, 2025

MicroRNA biomarkers for predicting treatment response and resistance to bevacizumab in cancer

Zahra Monzavi Chaleshtori Sanaz Darash Sarvenaz Parsa Elahe Orak Sarkani Motahareh Taghizadeh

Omid Vakili

Clinica Chimica Acta Vol. 577 pp. 120472 · Elsevier BV

View at Publisher Save 10.1016/j.cca.2025.120472

Topics

No keywords indexed for this article. Browse by subject →

References

139

[1]

Ferrara "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer" Nat. Rev. Drug Discov. (2004) 10.1038/nrd1381

[2]

Machine learning applications in cancer prognosis and prediction

Konstantina Kourou, Themis P. Exarchos, Konstantinos P. Exarchos et al.

Computational and Structural Biotechnology Journal 2015 10.1016/j.csbj.2014.11.005

[3]

Dhanyamraju "Drug resistance mechanisms in cancers: Execution of pro-survival strategies" J. Biomed. Res. (2024) 10.7555/jbr.37.20230248

[4]

Mafi "Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment" Cell. Mol. Biol. Lett. (2022) 10.1186/s11658-022-00354-4

[5]

Regulatory Mechanism of MicroRNA Expression in Cancer

Zainab Ali Syeda, Siu Semar Saratu’ Langden, Choijamts Munkhzul et al.

International Journal of Molecular Sciences 2020 10.3390/ijms21051723

[6]

Budakoti "Micro-RNA: the darkhorse of cancer" Cell. Signal. (2021) 10.1016/j.cellsig.2021.109995

[7]

Hussen "MicroRNA: a signature for cancer progression" Biomed. Pharmacother. (2021) 10.1016/j.biopha.2021.111528

[8]

Kiss "MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX" Oncol. Lett. (2017) 10.3892/ol.2017.6255

[9]

Dudley "Pathological angiogenesis: mechanisms and therapeutic strategies" Angiogenesis (2023) 10.1007/s10456-023-09876-7

[10]

Wang "Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis" Front. Pharmacol. (2023)

[11]

Wang "Direct antitumor activity of bevacizumab: an overlooked mechanism?" Front. Pharmacol. (2024)

[12]

Cursiefen "VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment" J. Clin. Invest. (2004) 10.1172/jci20465

[13]

Shibuya "Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis" Angiogenesis (2006) 10.1007/s10456-006-9055-8

[14]

Garcia "Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook" Cancer Treat. Rev. (2020) 10.1016/j.ctrv.2020.102017

[15]

Pavlidis "Role of bevacizumab in colorectal cancer growth and its adverse effects: a review" World J. Gastroenterol. (2013) 10.3748/wjg.v19.i31.5051

[16]

Higgins "Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model" Anticancer Res. (2007)

[17]

Martino "Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients" Cell Death Discov. (2016) 10.1038/cddiscovery.2016.25

[18]

Ghiaseddin "Use of bevacizumab in recurrent glioblastoma" CNS Oncol. (2015) 10.2217/cns.15.8

[19]

Escudier "Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival" J. Clin. Oncol. (2010) 10.1200/jco.2009.26.7849

[20]

Marchetti "First-line treatment of women with advanced ovarian cancer: focus on bevacizumab" Onco Targets Ther. (2019) 10.2147/ott.s155425

[21]

Haibe "Resistance mechanisms to anti-angiogenic therapies in cancer" Front. Oncol. (2020) 10.3389/fonc.2020.00221

[22]

Ortiz "Mechanisms of chemotherapy resistance in ovarian cancer" Cancer Drug Resist. (2022)

[23]

Zhang "Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies" Front. Bioeng. Biotechnol. (2025) 10.3389/fbioe.2025.1589841

[24]

Bergers "The role of pericytes in blood-vessel formation and maintenance" Neuro Oncol. (2005) 10.1215/s1152851705000232

[25]

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Rakesh K. Jain

Science 2005 10.1126/science.1104819

[26]

García "Anti-angiogenic therapy for ovarian cancer" Eur. J. Cancer Suppl. (2020) 10.1016/j.ejcsup.2020.02.003

[27]

Hurwitz "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" N. Engl. J. Med. (2004) 10.1056/nejmoa032691

[28]

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Kathy D. Miller, Linnea I. Chap, Frankie A. Holmes et al.

Journal of Clinical Oncology 2005 10.1200/jco.2005.05.098

[29]

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal et al.

Journal of Clinical Oncology 2009 10.1200/jco.2007.14.5466

[30]

Vredenburgh "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme" J. Clin. Oncol. (2007) 10.1200/jco.2007.12.2440

[31]

Tewari "Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer" J. Clin. Oncol. (2019) 10.1200/jco.19.01009

[32]

Vishnoi "miRNA biogenesis and regulation of diseases: an updated overview" MicroRNA Profiling: Methods and Protocols. (2022)

[33]

Hill "miRNA interplay: mechanisms and consequences in cancer" Dis. Model. Mech. (2021) 10.1242/dmm.047662

[34]

Regulation of microRNA biogenesis

Minju Ha, V. Narry Kim

Nature Reviews Molecular Cell Biology 2014 10.1038/nrm3838

[35]

O'Brien "Overview of microRNA biogenesis, mechanisms of actions, and circulation" Front. Endocrinol. (Lausanne). (2018) 10.3389/fendo.2018.00402

[36]

Havens "Biogenesis of mammalian microRNAs by a non-canonical processing pathway" Nucleic Acids Res. (2012) 10.1093/nar/gks026

[37]

miRNAs in Cancer (Review of Literature)

Beata Smolarz, Adam Durczyński, Hanna Romanowicz et al.

International Journal of Molecular Sciences 2022 10.3390/ijms23052805

[38]

Chen "Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy" Apoptosis (2014) 10.1007/s10495-014-0999-7

[39]

Yang "MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma" Oncol. Rep. (2016) 10.3892/or.2016.5129

[40]

Chiang "MiR-182 promotes proliferation and invasion and elevates the HIF-1alpha-VEGF-A axis in breast cancer cells by targeting FBXW7" Am. J. Cancer Res. (2016)

[41]

Zheng "Regulation of angiogenesis by microRNAs in cancer" Mol. Med. Rep. (2021) 10.3892/mmr.2021.12222

[42]

Goradel "Regulation of tumor angiogenesis by microRNAs: state of the art" J. Cell. Physiol. (2019) 10.1002/jcp.27051

[43]

MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer

Y Lu, T Qin, J Li et al.

Cancer Gene Therapy 2017 10.1038/cgt.2017.30

[44]

Chen "P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2" Cell Death Dis. (2019) 10.1038/s41419-018-1188-3

[45]

Chen "miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer" Aging (Albany NY) (2018) 10.18632/aging.101656

[46]

Berindan-Neagoe "MicroRNAome genome: a treasure for cancer diagnosis and therapy" CA Cancer J. Clin. (2014)

[47]

Reda El Sayed "MicroRNA therapeutics in cancer current advances and challenges" Cancers (Basel) (2021) 10.3390/cancers13112680

[48]

Menon "miRNA: A promising therapeutic target in cancer" Int. J. Mol. Sci. (2022) 10.3390/ijms231911502

[49]

Melo "Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing" Proc. Natl. Acad. Sci. U.S.A. (2011) 10.1073/pnas.1014720108

[50]

Dhuri "Simultaneous targeting of multiple oncomiRs with phosphorothioate or PNA-based anti-miRs in lymphoma cell lines" Pharm. Res. (2022) 10.1007/s11095-022-03383-y

Showing 50 of 139 references

Metrics

1

Citations

139

References

Details

Published: Sep 01, 2025
Vol/Issue: 577
Pages: 120472
License: View

Authors

Z

Zahra Monzavi Chaleshtori

Cite This Article

Zahra Monzavi Chaleshtori, Sanaz Darash, Sarvenaz Parsa, et al. (2025). MicroRNA biomarkers for predicting treatment response and resistance to bevacizumab in cancer. Clinica Chimica Acta, 577, 120472. https://doi.org/10.1016/j.cca.2025.120472

MicroRNA biomarkers for predicting treatment response and resistance to bevacizumab in cancer

You May Also Like